Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
- 1st Edition - June 6, 2023
- Imprint: Academic Press
- Editors: Heba Mohamed Mansour, Mahmoud Mohamed Khattab, Aiman El-Khatib
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 6 7 7 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 6 7 8 - 3
Overexpression of receptor tyrosine kinases (RTKs) has been implicated in cancer. Increasing evidence suggests that dysregulation of RTKs is reported in many neurodegenerative an… Read more
Purchase options
Overexpression of receptor tyrosine kinases (RTKs) has been implicated in cancer. Increasing evidence suggests that dysregulation of RTKs is reported in many neurodegenerative and psychiatric disorders.
Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders provides a fundamental, pragmatic map of RTKs structure, activation, functions, mechanism of action, gene regulation, and signaling pathways in developing central nervous system (CNS), adult normal CNS, neurodegenerative and psychiatric disorders. Additionally, the structure, function, activation, and therapeutic potential of many growth factors have been covered. Here, international experts in the field offer a comprehensive discussion of results of pre-clinical and clinical studies of repositioning of anti-cancer receptor tyrosine kinase inhibitors (RTKIs) and other promising protein kinase inhibitors in various neurodegenerative disorders including, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis, and psychiatric disorders including, anxiety, depression, alcohol use disorder, and schizophrenia. In addition, the book discusses the obstacles and opportunities for the potential repositioning of kinase inhibitors in neurodegenerative and psychiatric disorders.
- Provides a thorough overview of RTKs biology and their role in health and disease progression and modulation
- Highlights RTK families and the numerous receptors within each subfamily
- Examines RTKIs and other protein kinase inhibitors in pre-clinical and clinical trials in both neurodegenerative and psychiatric disorders
- Gives future directions of possible safe effective targeted RTKIs and other protein kinase inhibitors that may be repositioned in various neurodegenerative and psychiatric disorders
- Includes chapter contributions from renowned experts in biology, pharmacology, neurology, psychiatry, and oncology
- Researchers in cell biology, neuroscience, clinical pharmacology, basic pharmacology, molecular biology, genetics, psychiatry, immunology, oncology, and pathology.
- Industrial companies develop kinase inhibitors, and industry research scientists work in the fields of clinical neuroscience and molecular and cellular neuroscience.
1. The Molecular Pathology of Neurodegenerative And Psychiatric Disorders
2. Receptor Tyrosine Kinases: An Overview
3. Roles of TRK Receptors, Tyrosine Kinase Receptors for Neurotrophins, in the Developing CNS
4. Receptor Tyrosine Kinase (RTKs): from biology to pathophysiology
5. Growth Factors and Their Receptors: Multitasking Functionality in Health and Disease
6. Regulation of Receptor Tyrosine Kinase Gene Expression
7. Role Of Receptor Tyrosine Kinases in Neurodegenerative Disorders
8. Insights into Receptor Tyrosine Kinase Signaling in Neurodegenerative Disorders: Opportunities and Translational Perspectives
9. Receptor Tyrosine Kinases in Major Depressive Disorder
10. Repositioning of Receptor Tyrosine Kinase Inhibitors: From Cancer to Neurodegenerative And Psychiatric Disorders
11. Protein Kinase Inhibitors as Therapeutics in Neurodegenerative and Psychiatric Disorders: Progress, Challenges, and Recommendations
- Edition: 1
- Published: June 6, 2023
- Imprint: Academic Press
- Language: English
HM
Heba Mohamed Mansour
Heba Mohamed Mansour, Ph.D. is currently the Manager of the Innovative Products' Technical Evaluation Unit at the Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-Inn) at the Egyptian Drug Authority (EDA). She is a topic leader in the ICH working group (EWG S13), specializing in non-clinical safety assessments of oligonucleotide-based therapeutics (ONTs). Heba received a PhD degree in pharmacology and toxicology from the Faculty of Pharmacy, Cairo University in 2024. Her expertise encompasses a profound understanding of diverse cell death modalities in neurodegeneration and the exploration of potential drug repositioning strategies involving anti-cancer kinase inhibitors for neurodegenerative disorders. Her contributions extend to numerous research articles, prestigious international journal publications, book chapters, books, and comprehensive review articles, solidifying her interest in the field.
Affiliations and expertise
Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-INN), Egyptian Drug Authority (EDA), EgyptMK
Mahmoud Mohamed Khattab
Prof. Dr. Mahmoud M. Khattab is emeritus professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University (FOPCU). Between 10-1994 to 12-1996, he was a Ph.D. Fellow in Nephrology Laboratory, at College of Medicine, Munster University, Munster, Germany. He worked as University Staff in Faculty of Pharmacy (2000-2006), and Faculty of Medicine (2008-2010), King Saud University, Riyadh, KSA. He joined German University in Cairo between 2006-2008. He worked as part-time staff in many Universities including Beni Suef University, 6 October University, and Ahram Canadian University. He has contributed to two postgraduate Diplomas at FOPCU, namely the Pharmacovigilance Diploma and IT-Based Clinical Toxicology Diploma. His current research interest includes RAS-based, and Tyrosine Kinase-based targeting therapies in neurodegenerative and musculoskeletal diseases. Management of chemotherapy-induced diseases including depression and neuropathy by repurposing of known pharmacological mechanisms is another area of interest. Furthermore, he has current research projects in Breast Cancer therapeutic-enhancing modalities, including nutritional one. Furthermore, He is a consultant member in many scientific committees at the Egyptian Drug Authority (EDA), including Pharmacovigilance, Cosmetic Products, Neuropsychiatry, Internal Medicine committees.
Affiliations and expertise
Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, EgyptAE
Aiman El-Khatib
Prof. Dr. Aiman Saad El-Khatib is currently the Vice President of the Egyptian Drug Authority. He is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He held several leadership positions in Cairo University including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in field of Theoretical and Applied Biological Sciences in 2004, Silver and Gold Medal of Merit from Egyptian Syndicate of Pharmacists in 2004 and 2005.
Affiliations and expertise
Vice President, Egyptian Drug Authority (EDA) and Professor of Pharmacology and Toxicology, Cairo University, Cairo, EgyptRead Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders on ScienceDirect